Yuzhpharm, a pharmaceutical company in Troitskaya village, Krymsk district, Krasnodar Territory, plans to launch four import-substituting generic production lines across various dosage forms by the end of August. The project’s investments are estimated at 200 million rubles, according to the press service of the Region’s Ministry of Industrial Policy, as reported by Vedomosti Yug.
Yuzhpharm, a pharmaceutical company established in 2007, produces its own medicines and offers contract manufacturing services for other firms, including Vita Line, Alvils, and Moskhimpharmpreparaty named after N. A. Semashko. Mikhail Kravchuk is the owner and general director; he is also the founder of two additional companies, Morelor and Bronkhofen, both registered in the Karachay-Cherkessia Republic.
In 2023, Yuzhpharm received a subsidy to cover costs related to the production of import-substituting products in the region.
According to the publication, from January to May 2025, enterprises of the Krasnodar Territory specializing in the production of medicines and medical materials shipped products totaling 2.9 billion rubles, up 24% y-o-y, as well as medical instruments and equipment for 760 million rubles.
As of June 2025, there were 32 pharmaceutical enterprises operating in the region, compared to 36 in June 2024. Along with Yuzhpharm, these companies include the Armavir Biological Factory, the Steritek Infusion Solution Plant in Krasnodar, the Phytopharm in Anapa, and the Russ Arm Yug in Labinsk.